Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -108K | 0 | 0 | 0 | 0 |
| Operating Income | -15M | -26M | -21M | -22M | -14M |
| EBITDA | -15M | -19M | -22M | -19M | -14M |
| Net Income | -25M | -26M | -18M | -20M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.25
-7.41% today
1Y Change
-41.86%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theriva Biologics, Inc. (TOVX) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $0.25 and down 41.9% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +89.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +89.1%, free cash flow +1.4% with operating margin 0.0% and ROIC -86.1%. Stock Foundry combines TOVX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TOVX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TOVX Max Drawdown
-78.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TOVX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$14.3M
+27.5% YoY
Free Cash Flow
-$12.9M
+32.8% YoY
Revenue Growth
+0.0%
EPS Growth
+89.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -108K | 0 | 0 | 0 | 0 |
| Operating Income | -15M | -26M | -21M | -22M | -14M |
| EBITDA | -15M | -19M | -22M | -19M | -14M |
| Net Income | -25M | -26M | -18M | -20M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13M | 12M | 23M | 42M | 67M |
| Total Assets | 38M | 35M | 55M | 72M | 70M |
| Total Liabilities | 23M | 16M | 16M | 17M | 5M |
| Shareholder Equity | 15M | 19M | 40M | 55M | 65M |
| Total Debt | 3M | 2M | 2M | 2M | 2M |
| Net Debt | -10M | -10M | -21M | -40M | -66M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13M
+32.4% YoY
Capital Expenditures
14K
+87.9% YoY
Free Cash Flow
13M
+32.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-209.4%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.